Avastin

126,89 252,10 

Therapeutic VEGF-A-antibody from the original Avastin commercial drug targeting the VEGF-A-antigen, also referred to as Avastin antibody.

Category Product Concentration [mg/mL] Volume per Vial [µL] Quantity per vial [mg] Batch Number Manufacturing Year Availability Certificate of Analysis (CoA) PriceQuantityTotal
aliquot 251203H0152B2120151 wk No 155,46 
-
+
155,46 
spinner
aliquot 251203H0156B2120161 wk No 155,46 
-
+
155,46 
spinner
aliquot 25802B7219H0420161 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B7223H0620161 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B7223H1720161 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B7226H0720161 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B7230H1420171 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B7234H0220171 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B8020H0520171 wk No 126,89 
-
+
126,89 
spinner
aliquot 25802B8800H2820184 wksYes 126,89 
-
+
126,89 
spinner
dilution11000,1-20171 wk No 252,10 
-
+
252,10 
spinner

Category: SKU: B7219H04

Description

Additional information

Category

aliquot, dilution

Therapeutic molecule

Bevacizumab

Antigen

VEGF-A

Product Concentration [mg/mL]

1, 25

Volume per Vial [µL]

80, 100, 120

Quantity per vial [mg]

0, 0,1, 2, 3

Batch Number

B7219H04, B7223H06, B7223H17, B7226H07, B7230H14, B7234H02, B8020H05, NOT APPLICABLE, H0152B21, H0156B21, -, B8030H10, B8800H28

Manufacturing Year

2015, 2016, 2017, 2018, 2019

Availability

1 wk, 4 wks

Certificate of Analysis (CoA)

Yes, No